ArticleMolecular biotechnology2021
MiR-124-3p Suppresses Prostatic Carcinoma by Targeting PTGS2 Through the AKT/NF-κB Pathway.
Article in Molecular biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- PRR22: A Novel Prognostic Indicator and Therapeutic Target for Prostate Cancer.Anti-cancer agents in medicinal chemistry · 2026Article
- Exploration of the Biological Function of Ferroptosis in Bone Nonunion: An Analysis of Bioinformatics Combined Mendelian Randomization.Molecular biotechnology · 2026Article
- Unveiling prognostic biomarkers and immunotherapeutic insights in prostate cancer through multi-omics and machine learning.European journal of medical research · 2025Article
- miR-124-3p inhibits CRC proliferation, migration, and invasion by targeting ITGB1.Discover oncology · 2025Article
- Developing prognostic models for cholesterol-related genes linked with immune infiltration in prostate cancer.Frontiers in genetics · 2025Article
- Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- EIF3B stabilizes PTGS2 expression by counteracting MDM2-mediated ubiquitination to promote the development and progression of malignant melanoma.Cancer science · 2022Article
- Identification of candidate hub genes correlated with the pathogenesis, diagnosis, and prognosis of prostate cancer by integrated bioinformatics analysis.Translational cancer research · 2022Article
- The Impact of Oxidative Stress and AKT Pathway on Cancer Cell Functions and Its Application to Natural Products.Antioxidants (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MiR-124-3p had shown its tumor-regulatory properties in different cancers, but its potential roles in prostatic carcinoma had not been clearly understood. This study aimed to explore the roles of miR-124-3p in the regulation of prostatic carcinoma. The expression levels of PTGS2 and miR-124-3p were detected in prostatic carcinoma tissues and cultivated cell lines with qRT-PCR, immunohistochemistry and western blot, respectively. The interaction between miR-124-3p and PTGS2 was verified by the dual-luciferase reporter assay. Western blot, MTT, colony formation and flow cytometry assays were performed to evaluate the mediatory roles of miR-124-3p in prostatic carcinoma cells and the involvement of molecular pathways. Both prostatic carcinoma tissues and cells expressed a lower level of miR-124-3p and a higher level of PTGS2. PTGS2 was confirmed to be a target of miR-124-3p. MiR-124-3p suppressed cell viability, proliferation, migration, invasion and enhanced apoptosis of prostatic carcinoma cells by directly sponging PTGS2 to inhibit the AKT/NF-κB pathway. These findings provided information that miR-124-3p exerted anti-tumor effects in prostatic carcinoma by targeting PTGS2 to inactivate the AKT/NF-κB pathway. MiR-124-3p might have the potential to become an emerging therapeutic target for the treatment of prostatic carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.